Every 10-Q that ICU Medical Inc (ICUI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ICUI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICUI filings page.
ICU Medical reported total revenues of $551,683 (in thousands) for the quarter ended June 30, 2026, slightly above the prior year, while cost of goods sold declined to $316,630 (in thousands). Gross profit increased to $235,053 (in thousands) and income from operations rose to $39,127 (in thousands), aided by $18,900 (in thousands) of tariff refunds recorded within tariffs and duties. Quarterly net income was $19,087 (in thousands), compared with $35,338 (in thousands) a year earlier, when results included a $41,823 (in thousands) gain on a business sale.
For the first six months of 2026, net income reached $49,219 (in thousands), helped by a $27,644 (in thousands) income tax benefit driven largely by releases of unrecognized tax benefits. Net cash provided by operating activities improved to $119,059 (in thousands), while cash and cash equivalents were $298,299 (in thousands) and long‑term debt was $1,212,449 (in thousands) as of June 30, 2026 after $54,688 (in thousands) of principal repayments. The company continued restructuring and integration of the Smiths Medical acquisition, incurring $38,103 (in thousands) in related expenses and recording $7,922 (in thousands) of non‑cash lease impairments, and it is recognizing equity income and service revenues from its 40% stake in the Otsuka ICU Medical IV Solutions joint venture.
ICU Medical’s first quarter 2026 shows lower sales but a return to profitability. Revenue was $530.2 million versus $604.7 million a year earlier, mainly reflecting the prior sale of a majority interest in the IV Solutions business and lower Vital Care revenue. Operating income was $13.6 million compared with $12.9 million, as cost of goods sold and operating expenses declined. Net income improved to $30.1 million from a $15.5 million loss, helped by a $29.2 million discrete tax benefit from expiring statutes of limitations and valuation allowance changes. Cash from operations was $38.9 million, and ICU Medical ended the quarter with $288.3 million in cash and $1.28 billion of term loan debt after an October 2025 refinancing.
ICU Medical (ICUI) reported Q3 2025 results. Revenue was $536.99 million versus $589.13 million last year, with gross profit of $200.88 million. Operating income reached $13.72 million, but the company posted a net loss of $3.40 million (basic and diluted EPS -$0.14) as interest expense offset operating gains.
Year-to-date, revenue was $1.69 billion and net income $16.47 million, aided by a $44.79 million gain on sale of business tied to divesting a 60% stake in the IV Solutions business to OPF for $211.19 million cash and retaining a 40% equity-method interest. The retained interest was recorded at fair value and equity income was $1.30 million for the nine months (Q3 equity loss $1.54 million).
Cash and equivalents were $299.73 million, and long‑term debt declined to $1.31 billion from $1.53 billion at year‑end. Segment revenue mix in Q3: Consumables $285.09 million, Infusion Systems $173.91 million, and Vital Care $77.99 million. U.S. revenue was $307.13 million. Shares outstanding were 24,686,660 as of October 31, 2025.